Elicio Therapeutics, Inc.

Biotechnology • Healthcare • Boston, MA, United States • ELTX (NCM)

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

857 209 0050 451 D Street, Boston, MA 02210, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Elicio Therapeutics Secures $10 Million in Financing - Elicio Therapeutics

Elicio Therapeutics • Jun 4

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates - Yahoo Finance

Yahoo Finance • Nov 13

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial - Elicio Therapeutics

Elicio Therapeutics • Sep 17

Elicio Therapeutics: Running On Fumes, But A Definitive Readout Appears Imminent - Seeking Alpha

Seeking Alpha • Nov 7

Elicio Therapeutics (ELTX) upgraded to buy: Here's why - MSN

MSN • Dec 12

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Elicio Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Elicio Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Elicio Therapeutics, Inc. have?

Elicio Therapeutics, Inc. has approximately 32 employees.

What industry is Elicio Therapeutics, Inc. in?

Elicio Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Elicio Therapeutics, Inc. a publicly traded company?

Yes, Elicio Therapeutics, Inc. is publicly traded under the ticker symbol ELTX on the NCM. The company has a market capitalization of approximately $0.14 billion.

Where is Elicio Therapeutics, Inc. headquartered?

Elicio Therapeutics, Inc. is headquartered in Boston, MA, United States at 451 D Street, Boston, MA 02210, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.